Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Clinical Reasoning: A 34-year-old man with recurrent limb weakness
Neurol 77:e68-e72, Karam, C.,et al, 2011
A Randomized, Double-Blind, Placebo Controlled Trial of Simvastatin to Treat Alzheimer Disease
Neurol 77:556-563, Sano, M.,et al, 2011
A Rare Cause of Gait Ataxia
Lancet 378:1274, Rous, C.,et al, 2011
Association Between Stroke Center Hospitalization for Acute Ischemic Stroke and Mortality
JAMA 305:373-380, Xian,Y.,et al, 2011
Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:512-584, Goldstein,L.B.,et al, 2011
Blind, Breathless, and Paralysed from Benign Malaria
Lancet 377:438, Flower,B.,et al, 2011
Zoster Sine Herpete: Virologic Verification by Detection of Anti-VZV IgG Antibody in CSF
Neurol 76:484-485, Blumenthal,D.T.,et al, 2011
Bridging Intravenous-Inta-Arterial Rescue Strategy Increases Recanalization and the Likelihood of a Good Outcome in Nonresponder Intravenous Tissue Plasminogen Activator-Treated Patients: A Case-Control Study
Stroke 42:993-997, 880, Rubiera,M.,et al, 2011
Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator
Stroke 42:1041-1045, Vergouwen,M.D.I.,et al, 2011
Multimodal Imaging Does Not Delay Intravenous Thrombolytic Therapy in Acute Stroke
AJNR 32:864-68, Salottolo, K.M.,et al, 2011
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
An unusual cause of stroke and hypoxia
BMJ 342:c7200, Bell, S.L. & Eveson, D.J., 2011
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Statin Use Following Intracerebral Hemorrhage
Arch Neurol 68:573-579, Westover, M.B.,et al, 2011
Population-based study of wake-up strokes
Neurol 76:1662-1667, Mackey, J.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Autoimmune encephalitis
BMJ 342:d1918, Irani, S.R.,et all, 2011
A Case of Hashimoto Encephalopathy Clinical Manifestation, Imaging, Pathology, Treatment, and Prognosis
The Neurologist 17:141-143, Zhao, W.,et al, 2011
Lingual Hematoma After Thrombolytic Therapy
NEJM 364:e13, Vijayan,S. &Chase,A., 2011
Deep Brain Stimulation
JAMA 305:732, Pluta,R.,et al, 2011
Tumefactive Demyelination, an Uncommon Form of Tacrolimus Neurotoxicity
Neurol 76:672-674, Kim,S.H.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Pediatric Sciatic Neuropathies: A 30-year Prospective Study
Neurol 76:976-979, Srinivasan,J.,et al, 2011
Primary Varicella Zoster Infection Associated With Fingolimod Treatment
Neurol 76:1023-1024, Uccelli,A.,et al, 2011
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Rituximab Monotherapy for Patients With Recurrent Primary CNS Lymphoma
Neurol 76:929-930, Batchelor,T.T.,et al, 2011
Fulminant Encephalopathy With Basal Ganglia Hyperintensities in HIV-Infected Drug Users
Neurol 76:787-794, Newsome,S.D.,et al, 2011
Rituximab in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Report of 13 Cases and Review of the Literature
JNNP 82:306-308, Benedetti,L.,et al, 2011
Percutaneous Vascular Interventions for Acute Ischemic Stroke
Stroke 42:e31-e32, ORourke,K.,et al, 2011
Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age
JNNP 82:712-717, Bhatnagar, P.,et al, 2011
Encephalitis and antibodies to synaptic and neuronal cell surface proteins
Neurol 77:179-189, Lancaster, E.,et al, 2011
Neurological disturbances caused by intravascular lymphomatosis
Brain Nerve 63:443-449, Mizutani, T., 2011
Contemporary management and recent advances in paediatric hydrocephalus
BMJ 343:d4191, Kandasamy, J.,et al, 2011
Current Concepts and Management of Glioblastoma
Ann Neurol 70:9-21, Preusser, M.,et al, 2011
Subtherapeutic International Normalized Ratio in Warfarin-Treated Patients Increases the Risk for Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis
Stroke 42:2333-2335, Seet, R.C.S.,et al, 2011
Impact of Obesity on Stroke Outcome After Intravenous Thrombolysis
Stroke 42:2330-2332, Sarikaya, H.,et al, 2011
Efficacy of Intravenous Tissue-Type Plasminogen Activator in Central Retinal Artery Occlusion Report From a Randomized, Controlled Trial
Stroke 42:2229-2234, Chen, C.S.,et al, 2011
Iodinated Contrast Media and Cerebral Hemorrhage After Intravenous Thrombolysis
Stroke 42:2170-2174, MacDougall, N.J.J.,et al, 2011
Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis
Neurol 77:341-348, Strbian, D.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Guideline on the Management of Patients with Extracranial Carotid and Vertebral Artery Disease
Stroke 42:e420-e463, Brott, T.G.,et al, 2011
Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy
NEJM 365:285-287, Egan, A.,et al, 2011
Advanced Brain Imaging Studies Should Be Performed in Patients With Suspected Stroke Presenting Within 4.5 Hours of Symptom Onset
Stroke 42-2666-2667,2670, Parsons, M.W., 2011
Advanced Brain Imaging Studies Should Not Be Performed in Patients With Suspected Stroke Presenting Within 4.5 Hours of Symptom Onset
Stroke 42:2668-2669,2670, Lyden, P.D., 2011
Safety and Functional Outcome of Thrombolysis in Dissection-Related Ischemic Stroke A Meta-Analysis of Individual Patient Data
Stroke 42:2515-2520, Zinkstok, S.M.,et al, 2011
Effects of Extending the Time Window of Thrombolysis to 4.5 Hours Observations in the Swedish Stroke Register (Riks-Stroke)
Stroke 42:2492-2497, Asplund, K.,et al, 2011
Progressive Multifocal Leukoencephalopathy in Transplant Recipients
Ann Neurol 70:305-322, Mateen, F.J.,et al, 2011